High expression of AMAP1, an ARF6 effector, is associated with elevated levels of PD-L1 and fibrosis of pancreatic cancer

Схожие документы

• Inhibition of mutant KRAS-driven overexpression of ARF6 and MYC by an eIF4A inhibitor drug improves the effects of anti-PD-1 immunotherapy for pancreatic cancer
  по: Hashimoto, Ari, et al.
  Опубликовано: (2021)
• ARF6 and AMAP1 are major targets of KRAS and TP53 mutations to promote invasion, PD-L1 dynamics, and immune evasion of pancreatic cancer
  по: Hashimoto, Shigeru, et al.
  Опубликовано: (2019)
• Frequent overexpression of AMAP1, an Arf6 effector in cell invasion, is characteristic of the MMTV-PyMT rather than the MMTV-Neu human breast cancer model
  по: Otsuka, Yutaro, et al.
  Опубликовано: (2018)
• The EGFR-GEP100-Arf6-AMAP1 Signaling Pathway Specific to Breast Cancer Invasion and Metastasis(†)
  по: Sabe, Hisataka, et al.
  Опубликовано: (2009)
• Expression of AMAP1, an ArfGAP, provides novel targets to inhibit breast cancer invasive activities
  по: Onodera, Yasuhito, et al.
  Опубликовано: (2005)